Publications

Publications

Filter Results: (8) Arrow Down

Show Results For

Page 1 of 8 Results
Sort by

Are you looking for?

→Search All HBS Web
  • November 2012
  • Supplement

Amylin Pharmaceuticals (B)

By: Richard G. Hamermesh and Carin-Isabel Knoop
Amylin Pharmaceuticals brought two first-in-class diabetes drugs to market, Byetta and Symlin, in 2005, which were sold in over 80 countries with $650.7 million in sales by 2011. However, the company remained unprofitable as sales plateaued. The small pharmaceutical... View Details
Keywords: Pharmaceuticals; Bristol-Myers Squibb; Health Care and Treatment; Pharmaceutical Industry; United States
Related
  • November 2008
  • Case

Adnexus Therapeutics, Inc.: Considering the Exit

By: Vicki L. Sato and Rachel Gordon
Dr. John Mendlein, CEO of Adnexus Therapeutics Inc. (Adnexus), a private biotechnology company, must decide whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six-month collaboration or continue with Adnexus' planned IPO. View Details
Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Entrepreneurship; Initial Public Offering; Corporate Strategy; Biotechnology Industry
Related
  • November 2020
  • Case

Valuing Celgene's CVR

By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details
Keywords: Mergers and Acquisitions; Value; Valuation; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Biotechnology Industry; United States
Related
  • November 2020
  • Supplement

Valuing Celgene's CVR

By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details
Keywords: Mergers and Acquisitions; Value; Valuation; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Biotechnology Industry; United States
Related
  • November 2020
  • Teaching Note

Valuing Celgene's CVR

By: Benjamin C. Esty and Daniel Fisher
Teaching Note for HBS Case No. 221-031. When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA)... View Details
Keywords: Mergers and Acquisitions; Valuation; Value; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Biotechnology Industry; United States
Related
  • 25 Feb 2002
  • Research & Ideas

MNCs in Asia: Investing in the Future

difficult," responded Anthony C. Hooper, president of Bristol-Myers Squibb Intercontinental Region, recalling how last-minute pricing interference by the Chinese government wreaked havoc with the... View Details
Keywords: by Julia Hanna
  • 19 May 2009
  • First Look

First Look: May 19, 2009

Bristol-Myers Squibb (BMS) after a successful six-month collaboration or continue with Adnexus' planned IPO. Purchase this case: http://hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=609015 Arcadia... View Details
Keywords: Martha Lagace
  • 15 Jan 2013
  • First Look

First Look: January 15

Amgen, Inc. In 2012, Amylin was acquired by Bristol-Myers Squibb for $5.3 billion. Purchase this case:http://hbr.org/search/813091-PDF-ENG Rock Health Higgins, Robert F., and Ian McKowan CornellHarvard... View Details
Keywords: Sean Silverthorne

Are you looking for?

→Search All HBS Web